Migraine Prevention Moves Into Focus With New Clinical Trials
Studies offer hope that CGRP antibodies will lead to better treatment for disabling headaches.
Read More
A Roadmap to Lower a1c Control May Have CV Benefits
"It's not rocket science," says Ashok Balasubramanyam, MD.
Paul Kaufman Hopeful, Inspired for Future of Glaucoma Research
The esteemed ophthalmologist spoke of novel therapies, importance of collaboration.
Paul Kaufman on Unmet Needs for Glaucoma, Burgeoning Solutions
In the second leg of a weighty interview, Kaufman ruminates on what more is needed.
Nikolas London Details Cross-Sectional Analysis of anti-VEGF Drugs
Study evaluated trials of aflibercept and ranibizumab in retinal vein occlusion.
Anju Peters, MD, Updates Doctors on the Knowns and Unknowns of Food Allergy
Peters gave a primer on peanuts and more at Pri-Med West.
STD Update: Chlamydia Stays Simple as Gonorrhea Adapts
Richard Johnson, MD, kept the mood light while giving the latest in STD care.
While Understanding of Alzheimer's is Evolving, Countless Unanswered Questions Remain
Alzheimer's authority Gary Small, MD, gave detailed update of current treatment.
Paul Kaufman, MD, Speaks of His Motivations and Mission in Advance of Award and Lecture
The esteemed ophthalmologist was candid, thoughtful in deep interview with MD.
Quan Dong Nguyen on Pioneering Aflibercept, Ranibizumab, and Sirolimus
Nguyen has had the fortune of having been involved in the trials of all three.
Quan Dong Nguyen, MD, on Sirolimus's Potential to Change Uveitis Treatment
Nguyen speaks of the implications sirolimus could have if approved by the FDA.
Stanford's Quan Dong Nguyen, MD, Speaks on the SAKURA Trials
Researcher speaks on his team's findings regarding uveitis candidate sirolimus.
“You can really change the life of a patient quickly,†Anat Loewenstein Discusses ARVO, Ophthalmology
"I’ve been going to ARVO for 20 years...every year I learn a lot,†Loewenstein says.
Anat Loewenstein Talks ForeSeeHome, Unmet Needs in Retinal Disease
The biggest unmet need nowadays in retina disease is geographic atrophy..."
Anat Loewenstein Discusses UNRAVEL Trial of Ranibizumab and Aflibercept
It does show that there is a difference between the drugs,†she says.
Christine Birchwood Details the GiACTA Trial
Patients in tocilizumab treatment group 4 times more likely to see remission.
Christine Birchwood on the Significance of GiACTA
With many manifestations, giant cell arteritis must be addressed across specialties.
Machine Learning Could Change Understanding of AMD Progression, Severity
Algorithm able to correctly predict drusen progression with encouraging accuracy.
Reborn American Health Care Act Narrowly Passes House
On second try, the GOP has begun the process of repealing the ACA.
Pfizer Seeks to Expand Tofacitinib Approval to Include Psoriatic Arthritis
FDA to consider Xeljanz, the sole JAK inhibitor available in US, for new indication.
New Data on Teriflunomide, Alemtuzumab Announced at AAN 2017
Follow-up data from TOPIC, CARE-MS II trials positive for the two MS drugs.
Study: Brivaracetam Safe with Other Epilepsy Drugs
“Unlikely to have clinically relevant interactions with any commonly prescribed AEDs.â€
Sonja Potrebic, MD, Speaks on Importance and Challenges of Guideline Development
“When we make recommendations, we don’t just use the evidence from the studies.â€
ACT2 Trial Results Endorse Use of Vagus Nerve Stimulation in Episodic Cluster Headache
Study results coincide with FDA's recent decision on a stimulation device.
Nusinersen a Major Leap for Spinal Muscular Atrophy Treatment, According to Phase 3 CHERISH Trial
Phase 3 ARISE Trial Shows Erenumab's Migraine-Blocking Potential
Those treated experienced an average decrease of 2.9 monthly migraine days.
AAN Releases Guidelines for Sudden Unexpected Death in Epilepsy
Risk of death in epilepsy "almost the elephant in the room,†according to Donner.
Monoclonal Antibodies May Bring “New Era†in Migraine Prevention
"This is disease-specific, mechanism-based treatment," Amaal Starling enthuses.
Atrial Fibrillation, Loneliness Contribute to Gender Gap in Stroke Risk
Past studies of AF have under-represented women, according to Louise McCullough.
FDA Approves Infliximab Biosimilar
Infliximab-abda approved for range of gastroenterological and rheumatoid conditions.